"People come together, operators, with their supervisors at 6 a.m. every morning, and they talk about what issues they have and how they propose to solve it. Those get escalated through all levels of ...

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

As the potential of GLP-1 agonists for addiction gains traction, big pharma is also starting to take notice, namely the two ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Most medical devices in the United States come to market with limited clinical data, and device surveillance is viewed as a ...

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, citing ...

Researchers have conducted the first national survey on public awareness and perceptions of food, health, and Food is ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

The large inflow of cash from Comirnaty gross profits in 2021-22 has further secured BioNTech's financial health. Outside of BioNTech’s covid-19 vaccine candidates, we think the earliest approval ...

Seeking more efficient drug development, pharmaceutical giants and startups are encouraging AI fluency and in some cases ...